TY - JOUR AU - Schmitz, Ann Kristin AU - Sorg, Rüdiger V. AU - Stoffels, Gabriele AU - Grauer, Oliver M. AU - Galldiks, Norbert AU - Steiger, Hans-Jakob AU - Kamp, Marcel A. AU - Langen, Karl-Josef AU - Sabel, Michael AU - Rapp, Marion TI - Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine ( 18 F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients JO - British journal of neurosurgery VL - 35 IS - 6 SN - 1360-046X CY - London [u.a.] PB - Taylor & Francis M1 - FZJ-2019-04251 SP - 736-742 PY - 2021 AB - Objective: Vaccination therapy using tumour antigen-loaded, autologous dendritic cells (DC) is a promising therapeutic approach alongside standard treatment for glioblastoma (GBM). However, reliable diagnostic criteria regarding therapy monitoring are not established. Here, we analysed the impact of additional 18F-fluoroethyl-tyrosine positron emission tomography (18F-FET PET) imaging following DC vaccination therapy.Methods: We analysed data of GBM patients who received DC vaccination therapy. Following MRI diagnosis of tumour recurrence, additional static and dynamic 18F-FET PET imaging was performed. Vaccination was performed five times by intradermal injections, either weekly between concomitant radio/-chemotherapy and intermittent chemotherapy or after tumour recurrence, before re-radiation therapy. MRI and 18F-FET PET results were compared and correlated with clinical data.Results: Between 2003 and 2016, 5 patients were identified who received DC vaccination and 18F-FET PET imaging (1 female/4 males; mean age: 44 ± 14 y). 3/5 patients showed congruent results of tumour progression. In three patients 18F-FET PET indicated treatment related changes, which was in contrast to MRI findings that indicated tumour progression. In these patients 18F-FET PET results could be confirmed by either neuropathological diagnosis or according to the RANO criteriaConclusions: Despite the small patients number our results indicate an additional impact of 18F-FET PET for monitoring outcome following vaccination therapy. LB - PUB:(DE-HGF)16 C6 - 31407920 UR - <Go to ISI:>//WOS:000480905300001 DO - DOI:10.1080/02688697.2019.1639615 UR - https://juser.fz-juelich.de/record/864473 ER -